Huebner, G. and Link, H. and Kohne, C. H. and Stahl, M. and Kretzschmar, A. and Steinbach, S. and Folprecht, G. and Bernhard, H. and Al-Batran, S. E. and Schoffski, P. and Burkart, C. and Kullmann, F. and Otremba, B. and Menges, M. and Hoffmann, M. and Kaiser, U. and Aldaoud, A. and Jahn, A. (2009) Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. BRITISH JOURNAL OF CANCER, 100 (1). pp. 44-49. ISSN 0007-0920,
Full text not available from this repository. (Request a copy)Abstract
Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30% and median overall survival of 9-11 months in selected patients. Yet these combinations have not been subject to a randomised trial to overcome selection bias, a major problem in CUP. We randomised 92 patients to either paclitaxel/carboplatin (arm A) or the non-platinum non-taxane regimen gemcitabine/vinorelbine (arm B). The primary endpoint was rate of practicability as defined: application of >= 2 cycles of therapy ( 1) with a maximal delay of 1 week ( 2) and survival of >= 8 months ( 3). Practicability was shown in 52.4% (95% CI 36-68%) in arm A and in 42.2% ( 95% CI 28-58%) in arm B, respectively. The median overall survival, 1-year survival-rate and response rate of patients treated in arm A was 11.0 months, 38, and 23.8%, arm B 7.0 months, 29, and 20%. In conclusion, the paclitaxel/carboplatin regimen showed clinically meaningful activity in this randomised trial (Clinical trial registration number 219, 'Deutsches KrebsStudienRegister', German Cancer Society.)
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CANCER-RESEARCH-NETWORK; CELL LUNG-CANCER; PRIMARY SITE; PRIMARY TUMORS; CHEMOTHERAPY; EPIDEMIOLOGY; COMBINATION; CISPLATIN; ETOPOSIDE; DOCETAXEL; neoplasms; unknown primary; randomized controlled trial; clinical trial, phase II; medical oncology; anti-neoplastic-combined chemotherapy protocols |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Zentren des Universitätsklinikums Regensburg > Tumorzentrum e.V. |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 07 Oct 2020 09:38 |
| Last Modified: | 07 Oct 2020 09:38 |
| URI: | https://pred.uni-regensburg.de/id/eprint/29580 |
Actions (login required)
 |
View Item |
